Grant winners - 10 October 2013

October 10, 2013

Leverhulme Trust

Research Project Grants

Near field subwavelength resolution imaging in lossy inhomogeneous media

  • Award winner: Anjali Goswami
  • Institution: University College London
  • Value: £219,910

Walking the cat back: evolutionary mechanics and modularity of felid locomotion

How do cells protect their genes from pervasive transcription?

How plant roots cohere with soil



The role of nucleotide excision repair in providing resistance to the nucleoside analogues gemcitabine and cytarabine


Royal Society

Wolfson Research Merit Awards

Awards are worth £10,000-£30,000 a year, which is a salary enhancement.

Small molecule lipid bilayer anion transporters for biological applications

4D computer vision for real-world dynamic scene understanding

Very high-energy gamma-ray astrophysics in the UK


National Institute for Health Research

Efficacy and Mechanism Evaluation Programme

  • Award winner: Robert Howard
  • Institution: Institute of Psychiatry
  • Value: £1,846,405

Minocycline in Alzheimer’s disease efficacy trial: the MADE trial


Health Services and Delivery Research Programme

Optimal NHS service delivery to care homes: a realist evaluation of the features and mechanisms that support effective working for the continuing care of older people in residential settings

In detail

Health Technology Assessment Programme

Award winner: David Price
Institution: University of Aberdeen
Value: £2,118,845

A randomised, double-blind placebo controlled trial of the effectiveness of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation. In the UK, it affects about 3 million people and costs the NHS £1 billion a year. Some 60 per cent of the cost of treatment relates to exacerbations of the disease. Current treatment guidelines recommend inhaled corticosteroids (ICS) to reduce exacerbations and improve lung function. The airway inflammation in COPD is relatively insensitive to the anti-inflammatory effects of ICS, even at high doses. Preclinical and pilot studies demonstrate that low-dose theophylline may make airway inflammation more sensitive to ICS; thus it could be used with ICS to reduce the rate of COPD exacerbation. The researchers will investigate whether adding low-dose theophylline to ICS treatment cuts the rate of hospitalisation with exacerbations of COPD and makes patients feel better. They will determine the clinical effectiveness and cost- effectiveness of the procedure.

Please login or register to read this article

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments